Background
==========

In advanced breast cancer, chemotherapy is used for patients with estrogen receptor (ER) negative, endocrine resistant, or rapidly progressive disease to offer symptom control and improve survival. Whether to use combination chemotherapy or a sequential single agent chemotherapy strategy remains unclear. Combination chemotherapy is associated with higher response rates (RR) and improved time to progression (TTP) but the survival benefit is at its best modest and often linked with increased toxicity \[[@B1]\]. Therefore there is a need for tools that can identify those patients who will benefit the most from combination chemotherapy.

Breast cancer is recognized as a heterogeneous disease and response to treatment seems to depend on molecular characteristics of the tumor, some of which confer resistance to specific drugs while others confer a more multiresistant phenotype covering several different drug classes \[[@B2]-[@B8]\]. Predictive markers may serve as tools for tailoring therapy for individual patients, yet the number of clinically useful markers is still limited \[[@B9]-[@B11]\].

Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a multifunctional protein, where some of its functions are related to the inhibition of matrix metalloproteinases (MMPs) while other biological functions are MMP-independent, such as inhibition of apoptosis and stimulation of proliferation \[[@B12]-[@B16]\]. A prognostic value of TIMP- 1 in primary breast cancer has been suggested in several studies, with high plasma or tumor tissue content of TIMP-1 being associated with poor patient outcome \[[@B15]-[@B19]\]. Moreover, breast cancer patients with TIMP-1 positive cancer cells \[[@B2],[@B8],[@B20],[@B21]\] seem to benefit less from adjuvant anthracycline-containing chemotherapy. Docetaxel (D), a taxane disrupting the dynamic function of microtubules \[[@B22]\], and gemcitabine (G), a pyrimidine analog arresting DNA replication and synthesis \[[@B23]-[@B25]\], are widely used in breast cancer therapy \[[@B26],[@B27]\]. A phase III clinical trial by the Danish Breast Cancer Cooperative Group (DBCG) \[[@B28]\] compared the efficacy of D versus GD in patients with locally advanced or metastatic breast cancer. GD increased TTP by two months compared to D alone, while RR and overall survival (OS) were similar \[[@B28]\]. The purpose of the present study was to assess the potential predictive and prognostic information provided by TIMP-1 in patients participating in this trial. We have previously shown a differential benefit in these patients from the addition of G to D depending on intrinsic molecular subtype \[[@B29]\], and consequently we additionally sought to clarify whether a possible effect of TIMP-1 was independent of intrinsic subtypes.

Methods
=======

Patients
--------

The present study was based upon a DBCG randomized, phase III, multicenter trial previously described in detail \[[@B28]\]. The trial compared the efficacy of D to the combination of GD in 337 patients with histologically confirmed locally advanced or metastatic breast cancer. Patients were randomly assigned to D (100 mg/m^2^) day 1, every 21 days, or G (1000 mg/m^2^) days 1 and 8 plus D (75 mg/m^2^) day 8, every 21 days. Patients were either previously untreated, had received prior (neo)adjuvant chemotherapy or a single prior chemotherapy regimen, mostly anthracycline-based, for metastatic breast cancer. The majority of patients had *HER2* normal (68.8%) and hormone receptor positive disease (70.9%). More than half of the patients had visceral disease (57.3%). The type and amount of post-study chemotherapy were similar in the two arms. The study was conducted in accordance with the Declaration of Helsinki, and all patients gave their signed informed consent prior to study entry. DBCG prepared the original protocol as well as the biomarker supplement, and the Danish National Committee on Biomedical Research Ethics approved the original protocol and the supplement (KF 02-045-01 and KF 12 315632/H-KF-02-045-01) prior to activation.

TIMP-1 immunohistochemical staining
-----------------------------------

Expression of TIMP-1 protein was evaluated on formalin-fixed, paraffin-embedded (FFPE) primary tumor tissue whole sections (3 μm). The validated mouse monoclonal antibody (clone VT7) raised against recombinant human TIMP-1 \[[@B30],[@B31]\] was applied for immunohistochemical (IHC) staining as previously described \[[@B8]\]. In brief, sections were deparaffinized in xylene and rehydrated in graded concentrations of ethanol. For antigen retrieval, the sections were microwave treated in citrate buffer pH = 6 and endogen peroidase activity was blocked by hydrogen peroxide. Sections were incubated with VT7 (0.25 ug/ml) overnight at 4°C, and the antibody was detected with mouse/rabbit Advanced HRP (Code No. 4068, Dako A/S), and the reaction was visualized with DAB + (Code No. K5007, Dako A/S). TIMP-1 was assessed semi quantitatively using the positive (any cytoplasmatic staining of tumor cells, \> 0%) versus negative (no staining of tumor cells) staining signal as a measure of the TIMP-1 immunoreactivity in the epithelial breast cancer cells \[[@B2],[@B8],[@B20]\]. The whole-tissue sections were scanned and examined by light microscopy and reviewed blinded, without knowledge of patient characteristics and outcome, by three independent investigators (pathologist EB and two trained observers, technician AB and biologist CLTJ). The independent scores from all three investigators were consolidated into a final score. In case of discrepancies, agreement was reached by the three investigators evaluating the slides together.

Statistics
----------

Associations between TIMP-1 protein status and prognostic and demographic variables of the main study \[[@B28]\] and PAM50 intrinsic subtype \[[@B29]\] were assessed. Associations between TIMP-1 and categorical variables (treatment regimen, hormone receptor status, human epidermal growth factor receptor 2 (*HER2*) status, type of metastatic site, stage of disease, previous chemo-, hormonal-, and radiation-therapy, and PAM50 intrinsic subtype) were evaluated by Fisher's exact test, while associations between TIMP-1 and ordinal and interval variables (ECOG performance status, age at randomization, number of metastatic sites, and disease-free interval) were evaluated by the Wilcoxon rank sum test.

Time to progression (TTP) was the primary endpoint in the original trial \[[@B28]\] as well as in this biomarker sub-study, and secondary endpoints were overall survival (OS) and response rate (RR). TTP was measured from date of randomization to date of documented progression with censoring at date of last visit or death. OS was calculated from date of randomization to date of death with censoring for surviving patients at last visit date. Time-to-event endpoints (TTP and OS) were estimated by the Kaplan-Meier method, and associations to TIMP-1 status were evaluated by the log-rank test. Analyses of TIMP-1 were done unadjusted as well as adjusted for preselected covariates in multivariate Cox proportional hazards models. The preselected covariates were those found to be significant in the previous analysis of the main study \[[@B28]\] and in a subsequent correlative sub-study including PAM50 intrinsic subtype \[[@B29]\]: treatment regimen, disease type (visceral vs. nonvisceral), stage of disease, performance status, number of metastatic sites, and PAM50 intrinsic subtype. The adjusted model was further stratified for previous chemotherapy \[[@B28]\]. The assumption of proportional hazards was assessed by Schoenfeld residuals. Subgroup analyses were done to assess whether treatment effects on TTP and OS differed according to TIMP-1 status or the levels of preselected variables. In addition, explorative analysis of treatment effect heterogeneity according to the combined TIMP-1 and PAM50 intrinsic subtype status (TIMP-1 positive and non-basal-like vs. TIMP-1 negative and/or basal-like) was evaluated. The multivariate Cox proportional hazards model was extended by one interaction term at a time. The interaction terms were tested using the Wald test and results were given in a Forest plot. RR was evaluated for patients with measurable disease. The overall RR was defined as a complete or partial response according to RECIST criteria, version 1.0. RRs were compared by using Fisher's exact test.

Statistical analyses were conducted using SAS version 9.2 software package (SAS Institute, Cary, NC, USA). All statistical tests were two sided, and *P* \< 0.05 considered statistically significant. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) were adhered to wherever applicable \[[@B32]\]. The design of the study was prospective-retrospective as described by Simon et al. \[[@B33]\].

Results
=======

TIMP-1 IHC staining
-------------------

Archival FFPE primary tumor tissue blocks from patients enrolled in the trial were retrospectively collected between January 2006 and December 2010 from study sites and centrally stored. The original trial recruited 337 participants, and for the present study a total of 273 tumors were available for TIMP-1 analysis (Figure [1](#F1){ref-type="fig"}). TIMP-1 IHC staining was successful in 264 patients. The 264 TIMP-1 assessable patients differed significantly from the 73 non-assessable patients (P \< 0.05) with regard to stage of disease, (neo)adjuvant chemotherapy, adjuvant hormonal therapy, and adjuvant radiation therapy (Table [1](#T1){ref-type="table"}). Among the assessable 264 patients, 210 (80%) had a TIMP-1-positive tumor. TIMP-1 status was not correlated with any of the baseline characteristics (Table [2](#T2){ref-type="table"}).

![**CONSORT diagram.** \*Tissue samples were unavailable/unsuitable for one of the following reasons: archival tissue not available (n = 39), no tumor cells in available samples (n = 13), only needle biopsies available (n = 12). \*\*Tissue samples were withdrawn for one of the following reasons: IHC analysis done on metastasis only (n = 3), patients with bilateral cancer (n = 4), IHC analysis unsuccessful (n = 2). Abbreviations: D = docetaxel; DBCG = Danish Breast Cancer Cooperative Group; FFPE = formalin-fixed, paraffin-embedded; GD = gemcitabine plus docetaxel; IHC = immunohistochemical staining; TIMP-1 = tissue inhibitor of metalloproteinases-1.](1471-2407-14-360-1){#F1}

###### 

Patient demographics, disease characteristics, and prior therapy

                                             **Included**                   **Excluded**             
  ------------------------------------ ----- -------------- -------- ------ -------------- -------- ----------
  No. of patients                      264                           73                              
  Regimen                                                                                           0.36
     Docetaxel and Gemcitabine         137                  (51.9)   33                    (45.2)    
     Docetaxel                         127                  (48.1)   40                    (54.8)    
  Median age at randomization, years         59                             57                      0.57^e^
     Range                                   30-75                          36-73                    
  ECOG performance status                                                                           0.84
     0-1                               223                  (84.5)   65                    (89.0)    
     2                                 32                   (12.1)   8^a^                  (11.0)    
     Unknown                           9                    (3.4)    0                     (0.0)     
  Stage of disease                                                                                  0.049
     Locally advanced                  22                   (8.3)    12                    (16.4)    
     Metastatic                        242                  (91.7)   61                    (83.6)    
  No. of metastatic sites                                                                           0.74
     1                                 78                   (29.5)   18                    (24.7)    
     2                                 93                   (35.2)   27                    (37.0)    
     ≥ 3                               93                   (35.2)   28                    (38.4)    
  Type of metastatic site                                                                            
     Visceral                          150                  (56.8)   43                    (58.9)   0.79
     Lung                              78                   (29.5)   25                    (34.2)    
     Liver                             99                   (37.5)   27                    (37.0)    
     Non-visceral                      114                  (43.2)   30                    (41.1)    
     Bone                              175                  (66.3)   41                    (56.2)    
  Hormone receptor status                                                                           0.76
     Positive                          190                  (72.0)   49                    (67.1)    
     Negative                          70                   (26.5)   20                    (27.4)    
     Unknown                           4                    (1.5)    4                     (5.5)     
  *HER2* status^b^                                                                                  0.77
     Normal/deletion                   212                  (80.3)   20                    (27.4)    
     Amplification                     37                   (14.0)   4                     (5.5)     
     Unknown                           15                   (5.7)    49                    (67.1)    
  PAM50 subtype                                                                                     0.18
     Luminal A                         78                   (29.5)   6                     (8.2)     
     Luminal B                         94                   (35.6)   3                     (4.1)     
     Basal-like                        40                   (15.2)   3                     (4.1)     
     HER2-enriched                     46                   (17.4)   0                     (0.0)     
     Unknown                           6                    (2.3)    61                    (83.6)    
  Prior chemotherapy                                                                                 
     Total                             188                  (71.2)   45                    (61.6)   0.15
     (Neo)adjuvant                     127                  (48.1)   17                    (23.3)   0.0002
      Anthracycline                    71                   (26.9)   11                    (15.1)    
      Non-anthracycline                56                   (21.2)   6                     (8.2)     
     Locally advanced/metastatic       102                  (38.6)   31                    (42.5)   0.20
      Anthracycline                    86                   (32.6)   30                    (41.1)    
      Non-anthracycline                16                   (6.1)    1                     (1.4)     
  Hormonal therapy                                                                                   
     Total                             173                  (65.5)   41                    (56.2)   0.17
     Adjuvant                          119                  (45.1)   19                    (26.0)   0.006
     Locally advanced/metastatic       120                  (45.5)   37                    (50.7)   0.43
  Radiation therapy                    157                  (59.5)   22                    (30.1)   \<0.0001
  Disease-free interval, months^c^                                                                   
     Median                                  31                             22                      0.12^e^
     Range                                   0-250                          0-231                    

^a^Including one patient ECOG performance status 3.

^b^Retrospective analysis, primary tumor only.

^c^Time interval from diagnosis of primary cancer to recurrence.

^d^Fisher\'s exact test, unknown values excluded from tests.

^e^Wilcoxon test.

*Abbreviations*: *ECOG* Eastern Cooperative Oncology Group, *HER2* Human epidermal growth factor receptor 2.

###### 

Association between TIMP-1 status and patient demographics, disease characteristics, and prior therapy

                                            **TIMP-1 negative**                  **TIMP-1 positive**             
  ------------------------------------ ---- --------------------- -------- ----- --------------------- -------- ---------
  No. of patients                      54                                  210                                   
  Regimen                                                                                                       0.36
    Docetaxel and Gemcitabine          25                         (46.3)   112                         (53.3)    
    Docetaxel                          29                         (53.7)   98                          (46.7)    
  Median age at randomization, years        60                                   59                             0.79^e^
    Range                                   37-74                                30-75                           
  ECOG performance status                                                                                       0.91
    0-1                                47                         (87.0)   176                         (83.8)    
    2                                  6                          (11.1)   26                          (12.4)    
    Unknown                            1                          (1.9)    8                           (3.8)     
  Stage of disease                                                                                              0.58
    Locally advanced                   3                          (5.6)    19                          (9.0)     
    Metastatic                         51                         (94.4)   191                         (91.0)    
  No. of metastatic sites                                                                                       0.40
    1                                  12                         (22.2)   66                          (31.4)    
    2                                  22                         (40.7)   71                          (33.8)    
    ≥ 3                                20                         (37.0)   73                          (34.8)    
  Type of metastatic site                                                                                        
    Visceral                           31                         (57.4)   119                         (56.7)   1.00
    Lung                               17                         (31.5)   61                          (29.0)   0.87
    Liver                              18                         (33.3)   81                          (38.6)   0.44
    Non-visceral                       23                         (42.6)   91                          (43.3)    
    Bone                               33                         (61.1)   142                         (67.6)   0.42
  Hormone receptor status                                                                                       0.30
    Positive                           42                         (77.8)   148                         (70.5)    
    Negative                           11                         (20.4)   59                          (28.1)    
    Unknown                            1                          (1.9)    3                           (1.4)     
  *HER2* status^a^                                                                                              0.66
    Normal/deletion                    40                         (74.1)   172                         (81.9)    
    Amplification                      8                          (14.8)   29                          (13.8)    
    Unknown                            6                          (11.1)   9                           (4.3)     
  PAM50 subtype                                                                                                 0.89
    Luminal A                          15                         (27.8)   63                          (30.0)    
    Luminal B                          20                         (37.0)   74                          (35.2)    
    Basal-like                         7                          (13.0)   33                          (15.7)    
    HER2-enriched                      11                         (20.4)   35                          (16.7)    
    Unknown                            1                          (1.9)    5                           (2.4)     
  Prior chemotherapy                                                                                             
    Total                              37                         (68.5)   151                         (71.9)   0.62
    (Neo)adjuvant                      23                         (42.6)   104                         (49.5)   0.45
     Anthracycline                     14                         (25.9)   57                          (27.1)    
     Non-anthracycline                 9                          (16.7)   47                          (22.4)    
    Locally advanced/metastatic        21                         (38.9)   81                          (38.6)   1.00
     Anthracycline                     15                         (27.8)   71                          (33.8)    
     Non-anthracycline                 6                          (11.1)   10                          (4.8)     
  Hormonal therapy                                                                                               
    Total                              36                         (66.7)   137                         (65.2)   0.87
    Adjuvant                           24                         (44.4)   95                          (45.2)   1.00
    Locally advanced/metastatic        27                         (50.0)   93                          (44.3)   0.54
  Radiation therapy                    33                         (61.1)   124                         (59.0)   0.88
  Disease-free interval, months^b^                                                                               
    Median                                  36                                   31                             0.41^e^
    Range                                   0-224                                0-250                           

^a^Retrospective analysis, primary tumor only.

^b^Time interval from diagnosis of primary cancer to recurrence.

^c^Fisher\'s exact test, unknown values excluded from tests.

^e^Wilcoxon test.

*Abbreviations*: *ECOG* Eastern Cooperative Oncology Group, *HER2* Human epidermal growth factor receptor 2, *TIMP-1* Tissue inhibitor of metalloproteinases-1.

Prognosis and response rates
----------------------------

In univariate analyses, TIMP-1 status was not associated with TTP or OS, however, there was a non-significant trend that TIMP-1 positive patients had increased OS (P = 0.06) (Figure [2](#F2){ref-type="fig"}) (Table [3](#T3){ref-type="table"}).

![**Time to progression and overall survival according to TIMP-1 status.** Kaplan-Meier curve for **(A)** time to progression (165 events) and **(B)** overall survival (240 events) for all 264 advanced breast cancer patients treated with gemcitabine plus docetaxel or docetaxel alone (study arms combined) according to TIMP-1 immunohistochemical staining status. Abbreviations: CI = confidence interval; TIMP-1 = tissue inhibitor of metalloproteinases-1.](1471-2407-14-360-2){#F2}

###### 

**Cox univariate models for time to progression and overall survival**^**a**^

                                                **Time to progression**                          **Overall survival**            
  -------------------------------- ----- ------ ------------------------- ------- ------ ------- ---------------------- ------- ------
  TIMP-1 (positive vs. negative)   264   0.90   (0.61-                    1.31)   0.57   0.742   (0.55-                 1.01)   0.06

^a^Models not stratified.

*Abbreviations*: *CI* Confidence interval, *HR* Hazard ratio, *TIMP-1* Tissue inhibitor of metalloproteinases-1.

Treatment effects in the study population were similar to those found in the original study \[[@B28]\] (TTP: adjusted HR = 0.60; 95% CI 0.42-0.84; P = 0.003; OS: adjusted HR = 0.88; 95% CI 0.67-1.15; P = 0.34) (Table [4](#T4){ref-type="table"}).

###### 

**Cox multivariable models for time to progression and overall survival**^**a**^

                                                                         **Time to progression**                            **Overall survival**            
  ---------------------------------------------------- -------- -------- ------------------------- ------- ------- -------- ---------------------- ------- ----------
  Regimen (GD vs. D)                                            0.60     (0.42-                    0.84)   0.003   0.88     (0.67-                 1.15)   0.34
  TIMP-1 (positive vs. negative)                                0.82     (0.55-                    1.21)   0.31    0.71     (0.52-                 0.98)   0.03
  PAM50                                                                                                    0.007                                           0.0001
    Luminal A                                          78       0.68     (0.45-                    1.04)   0.08    0.78     0.56                   1.08    0.14
    Luminal B                                          100^b^   1.00     referent                                  1.00     referent                        
    Basal-like                                         40       1.75     (1.05-                    2.92)   0.03    2.39     (1.56-                 3.64)   \<0.0001
    HER2-enriched                                      46       1.30     (0.82-                    2.07)   0.27    1.25     (0.85-                 1.84)   0.25
  Visceral disease (yes vs. no)                                 1.60     (1.07-                    2.39)   0.02    1.13     (0.84-                 1.53)   0.42
  Stage of disease (locally advanced vs. metastatic)   1.96     (1.02-   3.76)                     0.04    0.72    (0.42-   1.24)                  0.23    
  Metastatic sites (3+ vs. 1-2)                                 1.24     (0.86-                    1.77)   0.25    1.52     (1.13-                 2.04)   0.01
  ECOG performance status (2 vs. 0-1)                           1.19     (0.85-                    1.67)   0.31    1.47     (1.12-                 1.93)   0.006

^a^Models stratified for previous chemotherapy (none, n = 76; adjuvant, n = 86; locally advanced or metastatic, n = 102).

^b^Including 6 records with missing value of PAM50 molecular subtype.

*Abbreviations*: *CI* Confidence interval, *D* Docetaxel, *ECOG* Eastern Cooperative Oncology Group,*G* Gemcitabine, *HER2* Human epidermal growth factor receptor 2, *HR* Hazard ratio, *TIMP-1* Tissue inhibitor of metalloproteinases-1.

In Cox multivariate analysis adjusted for regimen, PAM50 subtype, presence of visceral disease, stage of disease, number of metastatic sites, and ECOG performance status, TIMP-1 positivity was an independent prognostic factor with regard to OS (adjusted HR = 0.71; 95% CI 0.52-0.98; P = 0.03) but not for TTP (adjusted HR = 0.82; 95% CI 0.55-1.21; P = 0.31) (Table [4](#T4){ref-type="table"}).

RR among the 164 patients with measurable disease did not differ significantly according to TIMP-1 status (Table [5](#T5){ref-type="table"}).

###### 

**Best overall response**^**a**^**by TIMP-1 protein status**^**b**^

                    **TIMP-1 Positive**   **TIMP-1 Negative**        
  ----------------- --------------------- --------------------- ---- ----------------
  CR                4                     (3.0)                 2    (6.3)
  PR                46                    (34.8)                9    (28.1)
  Total responses   50                    (37.9)                11   (34.4)
  (95% CI)          (24.2 to 40.8)                                   (30.7 to 69.4)
  SD                56                    (42.4)                15   (46.9)
  PD                15                    (11.4)                5    (15.6)
  Unknown           11                    (8.3)                 1    (3.1)
  Total             132                                         32    

^a^Measurable disease (n = 164).

^b^Total responses, Fisher\'s exact test P =0.84.

*Abbreviations*: *CI* Confidence interval, *CR* Complete response, *PD* Progressive disease, *PR* Partial response, *SD* Stable disease, *TIMP-1* Tissue inhibitor of metalloproteinases-1.

TIMP-1 subgroup analysis
------------------------

In unadjusted analysis an estimated gain in median OS of nine months was seen in the doublet arm compared to the monotherapy arm for patients with a TIMP-1 negative tumor (GD, median OS: 19.9 months, 95% CI = 14.5-28.5; D, median OS: 10.6 months, 95% CI = 7.9-16.5, log rank p = 0.053) (Figure [3](#F3){ref-type="fig"}A). No difference in OS according to regimen was detected in patients with TIMP-1 positive tumors (Figure [3](#F3){ref-type="fig"}B).

![**Overall survival according to TIMP-1 status and treatment.** Kaplan-Meier curve for overall survival for **(A)** TIMP-1 negative patients and **(B)** TIMP-1 positive patients according to treatment allocation. Abbreviations: CI = confidence interval; D = docetaxel; DG = docetaxel plus gemcitabine; TIMP-1 = tissue inhibitor of metalloproteinases-1; trt = treatment.](1471-2407-14-360-3){#F3}

In multivariate Cox regression analyses adjusted for the preselected covariates no interaction was demonstrated between TIMP-1 status and treatment regimens for TTP (Figure [4](#F4){ref-type="fig"}A). For OS a borderline significant interaction was demonstrated such that GD improved OS compared to D in patients with TIMP-1 negative tumors (Figure [4](#F4){ref-type="fig"}B P~interaction~ = 0.06).

![**Subgroup analyses.** Forest plots illustrating hazard ratio (HR) estimates of treatment effect with 95% confidence intervals (CI) for **(A)** time to progression and **(B)** overall survival comparison between patients with TIMP-1 negative and TIMP-1 positive tumors, basal-like and non-basal-like tumors, TIMP-1 negative and/or basal-like (G responsive) and TIMP-1 positive and non-basal-like tumors (G nonresponsive). Abbreviations: D = docetaxel; G = gemcitabine; TIMP-1 = tissue inhibitor of metalloproteinases-1.](1471-2407-14-360-4){#F4}

Explorative analysis of gemcitabine responsive subgroup
-------------------------------------------------------

In this trial we have previously demonstrated a substantial reduction in mortality by GD compared to D in patients with basal-like tumors \[[@B29]\]. In the current study PAM50 intrinsic subtype remained an independent factor in the multivariate analysis with TIMP-1. To compare TIMP-1 as a single marker against the combination of TIMP-1 and PAM50 intrinsic subtype status further explorative analyses were conducted. A total of 87 (33%) patients were classified as G responsive (e.g. basal-like subtype and/or lack of TIMP-1 immunoreactivity). In Kaplan-Meier analysis patients classified as G responsive had a significant improvement in both TTP (GD, median TTP: 10.3 months, 95% CI = 7.7-12.6; D, median TTP: 6.2 months, 95% CI = 4.1-9.5) and OS (GD, median OS: 17.4 months, 95% CI = 14.4-20.7; D, median OS: 10.0 months, 95% CI = 7.9-15.5) if treated with GD compared with D. Multivariate analysis adjusted for patient and tumor characteristics confirmed these results for OS (P~interaction~ = 0.02, Figure [4](#F4){ref-type="fig"}B) but not for TTP (P~interaction~ = 0.09, Figure [4](#F4){ref-type="fig"}A).

Discussion
==========

In the present study, TIMP-1 cancer cell immunoreactivity was associated with a reduction in mortality but not with a reduction in TTP events (primary endpoint). Furthermore, in patients without TIMP-1 cancer cell immunoreactivity, we identified a 46% relative reduction in mortality from the addition of G to D compared to single agent D, although this difference was not statistically significant (P~interaction~ = 0.06).

The majority of breast cancer studies on TIMP-1 and association with prognosis and response to chemotherapy have focused on patients receiving adjuvant chemotherapy \[[@B2],[@B8],[@B18],[@B20],[@B34]\], whereas only two studies have included patients with advanced breast cancer \[[@B35],[@B36]\]. These two studies both measured TIMP-1 levels in the primary tumors using an enzyme-linked immunosorbent assay-based approach and included patients receiving cyclophosphamide/methotrexate/5-fluorouracil or anthracycline-based chemotherapy. In the exploratory study by Schrohl et al. \[[@B36]\] results suggested that patients with high levels of TIMP-1 are less responsive to chemotherapy, but the study did not include an analysis of OS. On the other hand, the second study by Klintman et al. \[[@B35]\] which supports the association of TIMP-1 with objective response to chemotherapy, did not find TIMP-1 to be associated with either progression free survival (PFS) or OS. The results presented in this manuscript suggest that TIMP-1 protein expression in cancer cells in the primary tumor evaluated by IHC is associated with improved OS for advanced breast cancer patients receiving D or GD. The use of different methodologies and regimens does compromise the comparability of studies, and thus, the prognostic significance of TIMP-1 in advanced breast cancer remains unclear.

The predictive value of TIMP-1 in relation to chemotherapy has been evaluated in a few studies \[[@B2],[@B8],[@B20],[@B21]\] but to our knowledge the relationship between TIMP-1 and the effect of G has not been addressed previously in a preclinical or clinical setting. In the present study we found a borderline statistically significant difference in OS favoring GD over D alone for patients evaluated as TIMP-1 negative. TIMP-1 negative patients receiving GD increased their survival by almost 50% to a median survival of 19.9 months compared to 10.6 months for patients receiving D only. Whether this survival benefit can be attributed to the addition of G specifically or whether our findings suggest a more general effect of chemotherapy doublets/D containing doublets in advanced breast cancer remains speculative and hypothesis generating. We were, however, able to identify a subgroup of patients that derived clinically meaningful benefit from combination chemotherapy as compared to single agent chemotherapy using TIMP-1 immunoreactivity although the results did not reach statistical significance (P = 0.06).

Preclinical data suggest that the anti-apoptotic functions of TIMP-1 are mediated through the phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway \[[@B15],[@B37]\] and TIMP-1 in this manner protects cancer cells from the effects of chemotherapy and hence cancer cells lacking TIMP-1 would remain sensitive to chemotherapy. Interestingly, the PI3K/Akt pathway has previously been suggested to be implicated in gemcitabine resistance \[[@B38]\]. Other preclinical findings suggest that TIMP-1 modifies proliferation by direct regulation of the cell cycle by arresting cells in G1 phase \[[@B39]\]. This could possibly alter the response to cell cycle specific drugs such as G, as the cytotoxic effect of G is associated primarily with specific inhibition of cells in the S phase \[[@B25],[@B40]\]. Furthermore, low levels of TIMP-1 have been associated with sensitivity to anthracycline- \[[@B2],[@B8],[@B20],[@B21]\] and irinotecan-containing therapy \[[@B41]\]. Since anthracyclines are topoisomerase-2 inhibitors and irinotecan is a topoisomerase-1 inhibitor, TIMP-1 may particularly interact with topoisomerase inhibitors. G has been shown to poison topoisomerase I \[[@B42],[@B43]\], suggesting that TIMP-1 can influence the effect of G through this enzyme. Taken together, these findings, along with the results obtained in the present study, make a 'broader' predictive role of TIMP-1 in the treatment of breast cancer likely.

Clinical trials in advanced breast cancer and other solid tumors often use TTP and PFS as primary endpoints and surrogate markers for OS \[[@B44],[@B45]\]. However, an increase in TTP or PFS does not always translate into a survival benefit. On the other hand, the results presented here demonstrate that neither the prognostic impact of TIMP-1 nor the trend of interaction between TIMP-1 status and treatment regarding OS were reflected in the analysis of the primary endpoint TTP. A reason for this discrepancy could be related to the nine-weekly disease-evaluations used in the current trial, which may have generated a systematic bias and less precise evaluation of TTP as compared to the OS endpoint where the date of death is exact \[[@B44]\]. Given that both tumor promoting and inhibitory effects have been described for TIMP-1 \[[@B12]-[@B16]\], and that cellular TIMP-1 function depends on the surrounding microenvironment \[[@B46],[@B47]\] the discrepancy between endpoints could also be related to a biological role of TIMP-1 such that the role of TIMP-1 is different in the case of localized cancer compared to the advanced disease setting, perhaps by preventing further spread of metastasis at this stage.

We have previously shown in this trial a differential benefit from the addition of G to D in patients with a basal-like intrinsic subtype classified by the PAM50 assay \[[@B29]\]. The fact that TIMP-1 status was not associated with PAM50 intrinsic subtype, suggests that TIMP-1 negative status and the basal-like subtype characterize two biologically distinct mechanisms of a possible G responsiveness. For comparison, in an exploratory analysis, we combined TIMP-1 and PAM50 subtype into a panel and classified patients as G responsive if tumors lacked TIMP-1 immunoreactivity and/or were characterized as basal-like, or otherwise as G nonresponsive. Using this panel 33% of the patients could be classified as G responsive compared with 20% and 15% using TIMP-1 status or PAM50 intrinsic subtype classification, respectively. The benefit from GD compared to D was considerably larger in patients with a G responsive profile, and this heterogeneity was confirmed by a statistically significant test of interaction between this panel and treatment for OS. Thus, the PAM50 intrinsic subtype/TIMP-1 protein status panel identifies the patients most likely to benefit from GD compared to D in terms of OS, and additionally, this panel appears to identify and separate two-thirds of the patients unlikely to derive any benefit from this combination therapy.

A strength of this study is that data from 78% of the patients enrolled in a randomized phase III clinical trial with long-term follow-up were available for analysis. In addition, we applied a previously validated assay for TIMP-1 immunoreactivity. On the other hand this study also has some potential limitations. The statistical power was limited due to the small population size, especially under-powering the results of the subgroup analysis. Another limitation is the fact that we did not include TIMP-1 staining of stromal cells in the analyses. It has been suggested that TIMP-1 may be produced by stromal cells and eventually become absorbed by breast cancer cells \[[@B48]\], and an association between stromal TIMP-1 expression status and progression of cancer has been reported \[[@B49],[@B50]\], although not consistently \[[@B51],[@B52]\]. In the current study TIMP-1 expression was exclusively evaluated in breast cancer cells, and the outcome might have been different if TIMP-1 had been evaluated in stromal cells or in stromal as well as cancer cells. Furthermore, TIMP-1 analysis was performed on primary tumor tissue and not on corresponding metastases. We cannot be sure that the status of TIMP-1 will be the same in the metastases as in the primary tumor since the molecular portrait of the tumor could have changed pronouncedly in the period in between primary diagnosis and recurrence, especially as a majority of the patients received prior treatment. A substantial discordance in ER and *HER2* status between primary and metastatic tumor tissue has been reported \[[@B53]-[@B55]\], and a study has demonstrated differences in the immunoreactivity of TIMP-1 in primary breast tumor tissue and the corresponding axillary lymph node metastasis \[[@B56]\]. TIMP-1 expression in primary and metastatic tumor tissue have not been compared, but usage of metastatic tumor tissue could potentially have had an impact on the results.

Conclusions
===========

In summary, this retrospective analysis applied to a prospective clinical trial demonstrated that TIMP-1 status appears to contain an independent prognostic value regarding overall survival in patients with advanced breast cancer receiving chemotherapy. We demonstrated that OS was almost doubled for patients with a TIMP-1 negative status receiving the combination regimen as compared to single agent chemotherapy. However, the test for interaction between TIMP-1 status and treatment did only reach borderline significance. Furthermore, we could not show a similar reduction in TTP events, the pre-specified primary endpoint of this study. The results presented here need further validation in order to obtain convincing evidence that TIMP-1 may be used as a predictive marker to direct the use of G in combination with D for patients with advanced breast cancer.
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